BAYRY News 126.8400 Bayer Aktienges Ads (BAYRY)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bayer Aktienges Ads (BAYRY) 126.8400 $BAYRY

Global Bacterial Pneumonia Therapeutic Pipeline Review 2014 - Analysis of 6 Companies and 6 Drug Profiles
M2 - Tue Apr 15, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxbl8g/bacterial) has announced the addition of the "Bacterial Pneumonia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bacterial Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Pneumonia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bacterial Pneumonia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bacterial Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bacterial Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Bacterial Pneumonia - Companies Involved in Therapeutics Development - Paratek Pharmaceuticals, Inc. - Bayer AG - ImmuVen, Inc. - Biota Pharmaceuticals, Inc. - Humabs BioMed SA - Dong-A Socio Holdings Co Ltd Drug Profiles - amikacin - tedizolid phosphate - omadacycline tosylate - Gyrase Program - IMV-0123 - MAb Against S aureus For more information visit http://www.researchandmarkets.com/research/jxbl8g/bacterial

Why Is Regeneron Pharmaceuticals, Inc. Bucking the Downtrend?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Biotech stocks are awash in a sea of red for the most part right now. Turning to the gory details, 89% of biotechs finished in negative territory last week -- with the vast majority falling by double digits. Although this downturn is certainly...

Global Multiple Sclerosis Therapeutics Market 2013-2019 with Copaxone Dominating
M2 - Thu Apr 10, 7:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnx74j/multiple) has announced the addition of the "Global Multiple Sclerosis Therapeutics Market 2013-2019 with Copaxone Dominating" report to their offering. The Multiple Sclerosis (MS) market has been growing consistently over the last two decades and is forecast to continue to grow from $8.1 billion in 2012 to $17.6 billion by 2019 at a CAGR of 11.6%. Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 2012-2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake. As a result of this, as well as an overall increase in the treated population, the authors believe the global market has the potential to grow to a value of $17.9 billion by 2019. Scope - A brief introduction to MS, including the disease's history, pathogenesis, risk factors and diagnosis. - In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy. - Comprehensive review of the pipeline for MS therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes. - Additional analysis of pipeline drug clinical trials by phase, molecule type, trial size and trial duration. - Multi-scenario forecast model of the market, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology. - Discussion of the drivers and barriers for market growth or decay. Key Topics Covered: - Tables & Figures - Introduction - Therapeutic Landscape - Pipeline for Multiple Sclerosis Therapeutics - Market Forecast to 2019 - Deals and Strategic Consolidations - Appendix Companies Mentioned - Bayer AG - Biogen - Biogen Idec - Elan Corporation - Genzyme Corporation - Merck Serono - Mitsubishi Tanabe - Novartis - Sanofi-Aventis - Teva Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/nnx74j/multiple

Analyzing the Chemical Industry in United States 2014
M2 - Wed Apr 09, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/43qn38/analyzing_the) has announced the addition of the "Analyzing the Chemical Industry in United States" report to their offering. The US Chemical Industry is one of the world's largest producer by a substantial margin with a balance of trade surplus in excess of $15 billion. It is a major player contributing 21% in GDP to the US economy. This growth has led many theorists to conclude that the industry is a harvester rather than an investor for future growth. Analyzing the Chemical Industry in United States researches the characteristics of the US chemical industry and the segments which, as a whole, make up this dynamic machinery of growth. The massive globalization strides taken by the industry as explained in the report with the requirement of heavy capital investment that brings in more competition and the overall focus of the industry to meet the environmental challenge. The report delves deeper into the processes applied in the US chemical industry and their defining global standards thereby ensuring leadership in exports as well as attracting FDI in the industry. The industry's dynamics like competition, infrastructure and the regulatory policies with the reporting requirements deployed on the industry are explained by the report. The progress of technology vis-?-vis the environmental costs as incurred by the industry are discussed in view of the energy demands of the industry. The report defines the industry in two major compartments as organic and inorganic sectors and the technologies employed by them. The report also profiles some of the leading players in the industry who have earned the reputation and pride for the US Chemical Industry globally and placing the United States at the top of the pecking order. Key Topics Covered: A. Executive Summary B. Introduction to the Industry C. Looking at Chemical Processing in the US D. Trade in the Industry E. Factors Influencing Competition in the Industry F. Looking at Technology involved in the Industry G. Environmental Costs of the US Chemical Industry and Restrictions on Chemical Products H. Looking at the Energy Demands of the Industry I. Energy Use and Energy Intensity of the Industry J. Foreign Investment in the Chemical Sector K. The Organic Chemical Industry in US L. The Inorganic Chemical Industry in US M. Leading Players N. Appendix O. Glossary of Terms Companies Mentioned - Bayer AG - BASF SE - ConocoPhillips - Dow Chemical Company - DuPont (EI) de Nemours - Eastman Chemical Company - Exxon Mobil Corporation - Huntsman Corporation - Monsanto Company Visit http://www.researchandmarkets.com/research/43...lyzing_the

Bayer USA Foundation Awards $600,000 to California State University East Bay
PR Newswire - Wed Apr 09, 2:01AM CDT
The Bayer USA Foundation, the philanthropic arm of Bayer Corporation, announced today it is awarding a new, three-year $600,000 grant to California State University's groundbreaking Institute for STEM Education (science, technology, engineering and mathematics) on the Hayward, Calif., campus.

Sanofi to File for Lemtrada Approval Again - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 6:09PM CDT
Sanofi announced that it plans to resubmit a supplemental Biologics License Application for Lemtrada.

Bayer Invests Over $400,000 in STEM Education and Workforce Development in Greater Houston
PR Newswire - Tue Apr 08, 7:30AM CDT
As demand grows in Greater Houston for more skilled and diverse STEM (science, technology, engineering and mathematics) workers, Bayer Corporation is meeting the challenge by investing more than $400,000 to strengthen STEM education and create a continuous STEM education-to-workforce pipeline in the Goose Creek Consolidated Independent School District (GCCISD) with grants and scholarships targeted to middle and high schools.

Global Nasopharyngitis (Common Cold) Clinical Trials Review
M2 - Mon Apr 07, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrbrn2/nasopharyngitis) has announced the addition of the "Nasopharyngitis (Common Cold) Global Clinical Trials Review, H2, 2013" report to their offering. Nasopharyngitis (Common Cold) Global Clinical Trials Review, H2, 2013" provides data on the Nasopharyngitis (Common Cold) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nasopharyngitis (Common Cold). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nasopharyngitis (Common Cold). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Nasopharyngitis (Common Cold) Therapeutics Clinical Trials - Bayer AG - Pfizer Inc. - Reckitt Benckiser Group Plc - Novartis AG - Marinomed Biotechnologie GmbH - GlaxoSmithKline plc - Merck & Co., Inc. - Daiichi Sankyo Company, Limited - Ache Laboratorios Farmaceuticos S/A - Bioforce AG Clinical Trial Overview of Top Institutes / Government - University of Wisconsin Madison - Hospital de Clinicas de Porto Alegre - National Center for Complementary and Alternative Medicine - University of Florida - University of Virginia - Charite - Universitatsmedizin Berlin - Royal Adelaide Hospital - China Academy of Chinese Medical Sciences - The Cleveland Clinic - Dresden University of Technology For more information visit http://www.researchandmarkets.com/research/zr...haryngitis

5 Biotechs With Prostate Cancer Treatments Worth Watching
George Budwell, The Motley Fool - Motley Fool - Sat Apr 05, 4:30PM CDT
In the United States, prostate cancer is now the most common type of malignancy detected in men. Even more concerning is that prostate cancer has crept up to the second-leading cause of cancer-specific deaths among men in the U.S., according to...

Bayer Initiates Xofigo Combination Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 4:30PM CDT
Bayer initiated a phase III study on Xofigo for the treatment of patients suffering from bone predominant metastatic CRPC.

Global Electronic Chemicals & Materials Market Report 2014 - Opportunities & Forecasts to 2019
M2 - Thu Apr 03, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hh5r7w/electronic) has announced the addition of the "Electronic Chemicals & Materials Market by Types, Application, Forms & Geography - Regional Trends & Forecast to 2019" report to their offering. The global electronic chemicals and materials market revenue was estimated to be $41 billion in 2013 is projected to grow at a CAGR of 6.3% from 2014 to 2019. The highest investment is forecasted to be in Asia-Pacific, due to the growing application markets, low cost of production, and availability of raw materials especially in China. ROW is expected to have the highest growth of 6.5% from 2014 to 2019. The North American and European segments are expected to share together 19% of the revenue by 2019, growing at the rates of 4.1% and 2.8%, respectively between 2014 and 2019. From 2010 to 2014, expansion was observed as the major growth strategy adopted by the electronic chemicals and materials companies, accounting for a share of 34.3% overall. In the first half of 2013, KMG Chemicals Company (U.S.) acquired ultra pure chemicals subsidiary of OM Group, followed by two expansions from The Linde Group (Germany), and three product launches by Dow Chemicals Company (U.S.). Cabot Microelectronic Corporation (U.S.) and Honeywell International Inc. (U.S.) are the other major participants in development activities during this period. The other active players in market development of electronic chemicals and materials are Air Liquide Holdings Inc. (France) and Albemarle Corporation (U.S.). Major companies offering electronic chemicals and materials are actively involved in launching new products in the market by investing in R&D. Irrespective of the company's size, all the market participants are actively investing in developing new products and delivering them to the market. The manufacturing companies are leveraging distribution networks of major companies by entering into strategic supply and distribution agreements. In this way, companies are able to explore new markets and penetrate into the existing markets with highly efficient products. Scope of the Report Type - Silicon Wafers - PCB Laminates - Specialty Gases - Photoresists - Wet Chemicals - CMP slurries - Low-K dielectric - Others Application - Semiconductors & Integrated Circuits (IC) - Printed Circuit Boards (PCB's) Form - Solid - Liquid - Gaseous Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Global Electronic Chemicals & Materials Market Overview - Electronic Chemicals & Materials Market, By Type - Electronic Chemicals & Materials Market, By Application - Electronic Chemicals & Materials Market, By Form - Electronic Chemicals & Materials Market, By Geography - Competitive Landscape - Company Profiles - Air Liquide Holdings Inc. - Air Products & Chemicals Inc. - Albemarle Corporation - Ashland Inc. - Az Electronic Materials Plc - Basf Se - Bayer Ag - Cabot Microelectronics Corporation - Honeywell International Inc. - Kmg Chemicals Inc. - Sunedison Llc - The Dow Chemical Company - The Linde Group For more information visit http://www.researchandmarkets.com/research/hh5r7w/electronic

Will Biogen Idec Inc. Rule Biotech in 2014?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 03, 8:30AM CDT
The biotech sector's endured an up-and-down 2014 after the immense gains captured in 2013's market rise, but don't tell that to fast-rising Biogen Idec . Biogen's stock has roared higher by more than 10% in 2014 after experiencing a tremendous...

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
M2 - Wed Apr 02, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qc2v39/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Sanofi - Johnson & Johnson - Novartis AG - Astellas Pharma Inc. - Takeda Pharmaceutical Company Limited - Bristol-Myers Squibb Company - Bayer AG - Medivation, Inc. - AstraZeneca PLC - Dendreon Corporation Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Memorial Sloan Kettering Cancer Center - Duke University - Barbara Ann Karmanos Cancer Institute - Swiss Group for Clinical Cancer Research - University of Wisconsin Madison - Stanford University For more information visit http://www.researchandmarkets.com/research/qc2v39/hormone

Bayer's Adempas Cleared in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:45PM CDT
Bayer's Adempas was approved in the EU for the CTEPH and PAH indications.

Is Your Portfolio Exposed to Corruption Risk?
Jillian Blake, The Motley Fool - Motley Fool - Tue Apr 01, 8:22AM CDT
In an increasingly globalized world, companies are taking advantage of business opportunities across borders and in new markets. While multinational corporations enjoy many benefits of their global reach, they also may face risks. One such risk is...

Business events scheduled for the coming month
By The Associated Press - AP - Fri Mar 28, 1:03PM CDT
TUESDAY, April 1

Simulations Plus Predictor improves all predictions, adds new ones
M2 - Thu Mar 27, 7:43AM CDT
Simulations Plus, Inc. (NASDAQ: SLP) said it has released version 7.0 of its best-in-class ADMET Predictor molecular property prediction software.

Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 27, 4:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rh34nq/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report on antibacterial drugs market studies the current as well as future prospects of the market globally. The market for antibacterial drugs is segmented on the basis of major classes of drugs, namely, aminoglycosides, B-lactams, tetracyclines, sulfonamides, quinolones/fluoroquinolones, macrolides and phenicols. The market for these classes has been extensively analyzed on the basis of the leading drug launch, expiry, efficacy, sales revenue and geographic presence. The market size and forecast in terms of USD million for each of these classes has been provided for the period 2011 to 2019, considering 2012 as the base year. The report on antibacterial drugs market also provides % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 to 2019. Key Topics Covered: Preface Executive Summary Market Overview Global Antibacterial Drugs Market Revenue, by Class, 2011 - 2019 (USD Million) Global Antibacterial Drugs Market Revenue, Pipeline Analysis (USD Million) Global Antibacterial Drugs Market Revenue, by Geography, 2011 - 2019 (USD Million) Competitive Landscape Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - AstraZeneca plc - Bayer AG - Bristol-Myers Squibb Company - Eli Lilly and Company - Forest Laboratories, Inc. - GlaxoSmithKline plc - Johnson & Johnson - Merck & Co., Inc. - Novartis AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/rh...ibacterial About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Simulations Plus Releases ADMET Predictor Version 7.0
Business Wire - Wed Mar 26, 7:02AM CDT
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has released version 7.0 of its best-in-class ADMET Predictor(TM) molecular property prediction software.

Bayer Names Carnegie Science Center Recipient of $150,000 Bayer USA Foundation Grant
PR Newswire - Wed Mar 26, 7:00AM CDT
Bayer Corporation announced today that the Bayer USA Foundation has awarded the Carnegie Science Center (CSC) a three-year grant totaling $150,000 to support a range of STEM-related (science, technology, engineering and mathematics) programs, events and competitions at CSC's new Center for STEM Education and Career Development.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 186

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 775

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 414

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 94

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 502

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 179

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 106

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 114

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading

Top 5 Most Recently Viewed Articles

Aitech Honored for Its Breakthrough in Rugged AI Technology

Updated Category News Views 382

Aitech Secures 2025 Artificial Intelligence Excellence Award Aitech, renowned for its rugged embedded systems tailored for military, aerospace, and space applications, has recently been distinguished as a winner in the 2025 Artificial Intelligence Excellence Awards organized by the Business Intelligence Group. This accolade celebrates the innovative strides in AI and...

Continue Reading
National Hydropower Association Emphasizes Hydropower's Importance

Updated Category News Views 129

National Hydropower Association Celebrates Hydropower Day The National Hydropower Association (NHA), the foremost trade association for the water power industry in the U.S., is excited to celebrate National Hydropower Day. This annual event pays tribute to the water power sector and the dedicated American workers who contribute to this essential renewable resource. The...

Continue Reading
Changing Perspectives: German Parents Embrace Cannabis Cultivation

Updated Category News Views 269

Changing Perspectives on Cannabis in Germany In Germany, the landscape of cannabis use has transformed remarkably in the past year. With the legislation on cannabis legalization now in effect, the cultural and social dynamics are evolving. Although there are mixed feelings on the topic, it's evident that younger people, particularly parents, are leaning towards supporting...

Continue Reading
Select Water Solutions Unveils 2025 Q1 Earnings Event Details

Updated Category News Views 257

Select Water Solutions Announces 2025 First Quarter Earnings Select Water Solutions, Inc. (NYSE: WTTR) is gearing up for the announcement of its financial performance for the first quarter of 2025. The company has confirmed the release date of these results, which is set to take place after the market closes on an upcoming Tuesday. This is an exciting time for investors...

Continue Reading
Colabor Group's Strategic Moves Shape Future Financial Outlook

Updated Category News Views 183

Colabor Group's Financial Performance Overview Colabor Group Inc. (TSX: GCL) reveals its financial results for the fourth quarter and fiscal year, providing insights into its ongoing market performance. Fourth Quarter Highlights In the fourth quarter, Colabor Group demonstrated resilience with a sales increase of 3.2%, reaching $202.6 million. Comparatively, sales were at...

Continue Reading